To that end, targeting neuroinflammation by modulating different phagocytic receptors e.g. CD33 inhibition [87] and/or TREM2 activation [88, 89] have been suggested as valuable therapeutic strategies to enhance neuroprotective microglia and reduce neuroinflammation, which is crucial for preventing and treating AD [85]. This evidence concerns the gene CD33 and Alzheimer disease.